Amrubicin monotherapy for refractory, relapsed, small cell lung cancer in elderly patients
Both hematological and non-infectious adverse events may have contributed to shorter progression-free survival in the high-dose group. Low-dose administration, granulocyte colony-stimulating factor support, and close monitoring for non-infectious toxicities may be important in elderly patients.
Authors
- Megumi Takemoto
- Yoko Furukawa‐Hibi (ORCID: https://orcid.org/0000-0002-2126-5652)
- Yuji Hotta (ORCID: https://orcid.org/0000-0002-9474-7775)
- Minami Asaoka (ORCID: https://orcid.org/0000-0002-7183-0365)
- Shiori Kinoshita (ORCID: https://orcid.org/0009-0007-9103-2276)
- Hirokazu Komatsu (ORCID: https://orcid.org/0000-0003-1627-3743)
- Kazuki Yamada (ORCID: https://orcid.org/0000-0001-8263-0011)
- Takehiro Uemura
Institutions
- Nagoya City University (JP)
- Nagoya City University Hospital (JP)
- Chita State Academy of Medicine (RU)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1093/jjco/hyaf140
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00